Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad Preservative (Travoprost 0.004%) Versus LUMIGAN 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma

Trial Profile

Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad Preservative (Travoprost 0.004%) Versus LUMIGAN 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2015

At a glance

  • Drugs Travoprost (Primary) ; Bimatoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 23 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top